Magnesium Sulfate Kalceks (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases Mg2+ ions that act as calcium antagonists at voltage‑gated channels. This leads to smooth‑muscle relaxation, vasodilation, reduced neuronal excitability, and stabilization of cardiac electrical activity, which together address electrolyte deficits and seizure risk.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goal. Healthcare professionals calculate the appropriate regimen and monitor serum magnesium levels throughout treatment.

Magnesium sulfate is commonly used in obstetric care, particularly for eclampsia prevention, but its safety profile in pregnancy is classified as unknown in some regions. It should only be used when clearly indicated and under medical supervision. Breastfeeding mothers should consult their physician, as limited data are available on excretion in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Magnesium Sulfate Kalceks is a sterile injectable solution, offering rapid systemic magnesium delivery compared with oral magnesium salts that have slower absorption and variable bioavailability. Its formulation is suitable for intravenous, intramuscular, or subcutaneous routes, providing precise control of plasma magnesium levels in acute settings.

The product should be stored at ambient temperature, protected from light and moisture, and kept in its original sealed container. Do not freeze the solution. Before use, inspect for particulate matter or discoloration and allow the vial to reach room temperature if refrigerated during transport.

Magnesium Sulfate Kalceks is administered by a qualified healthcare professional via intramuscular, intravenous, or subcutaneous injection. The route, infusion rate, and duration depend on the clinical indication and patient response, with continuous monitoring of vital signs and serum magnesium levels.

Serious risks include respiratory depression, severe hypotension, cardiac arrest, hypermagnesemia leading to loss of deep‑tendon reflexes, and profound muscle weakness. Prompt recognition of these signs and immediate cessation of infusion, along with supportive measures, are essential.

Patients with severe renal failure, uncontrolled heart block, myasthenia gravis, or known hypersensitivity to magnesium sulfate should avoid this product. It is also contraindicated in individuals receiving high doses of other magnesium‑containing agents without appropriate monitoring.